L.I.ON. Study: Efficacy and tolerability of continuous terbinafine (Lamisil®) compared to intermittent itraconazole in the treatment of toenail onychomycosis

British Journal of Dermatology, Supplement

Volumn 141, Issue 56, 1999, Pages 5-14

  Sigurgeirsson, B ^a   Billstein, S ^b   Rantanen, T ^c   Ruzicka, T ^g   Fonzo, E Di ^g   Vermeer, B J ^d   Goodfield, M J D ^e   Evans, E G V ^f  

^a Reykjavik City Hospital   (Iceland)

^b NOVARTIS PHARMA AG   (Switzerland)

^c PÄIJÄT HÄME CENTRAL HOSPITAL   (Finland)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e LEEDS GENERAL INFIRMARY   (United Kingdom)

^f UNIVERSITY OF LEEDS   (United Kingdom)

^g NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ITRACONAZOLE; TERBINAFINE;

ADULT; CLINICAL TRIAL; CONFERENCE PAPER; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYCOSIS; NAIL INFECTION; ONYCHOMYCOSIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL AGENTS; DOUBLE-BLIND METHOD; FEMALE; FOOT DERMATOSES; HUMANS; ITRACONAZOLE; MALE; MIDDLE AGED; NAPHTHALENES; ONYCHOMYCOSIS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0032759953     PISSN: 0366077X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (20)

1. Roberts DT. Prevalence of dermatophyte onychomycosis in the United Kingdom: results of an omnibus survey. Br J Dermatol 1992; 126 (Suppl. 39): 23-7.
2. Sais G, Jugglà A, Peryí J. Prevalence of dermatophyte onychomycosis in Spain: a cross-sectional study. Br J Dermatol 1995; 132: 758-61.
3. Heikkilä H, Stubb S. The prevalence of onychomycosis in Finland. Br J Dermatol 1995; 133: 699-703.
4. Gupta AK, Lynde CW, Jain HC, Sibbald RG, Elewski BE, Daniel CR 3rd et al. A higher prevalence of onychomycosis in psoriatics compared with non-psoriatics: a multicentre study. Br J Dermatol 1997; 136: 786-9.
5. Gudnadottir G, Hilmarsdottir I, Sigurgeirsson B. Onychomycosis in Icelandic swimmers. Acta Derm Venerol (Stockh) 1999; 79: 376-7.
6. Scher RK. Onychomycosis is more than a cosmetic problem. Br J Dermatol 1994; 130 (Suppl. 43): 15.
7. Lubeck DP. Quality of life in persons with onychomycosis. Qual Life Res 1993; 2: 341-8.
8. Chiritescu MM, Chiritescu M-E, Scher RK et al. Newer systemic antifungal drugs for the treatment of onychomycosis. Clin Podiatr Med Surg 1996; 13: 741-58.
9. De Backer M, De Keyser P, De Vroey C, Lesaffre E. A 12-week treatment for dermatophyte toe onychomycosis: terbinafine 250mg/day vs. itraconazole 200mg/day - a double-blind comparative trial. Br J Dermatol 1996; 134 (Suppl. 46): 16-7.
10. Bräutigam M, Nolting S, Schopf RE et al. Randomised double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection. Br Med J 1995; 311: 919-22.
11. Tosti A, Piraccini BM, Stinchi C et al. Treatment of dermatophyte nail infections: an open randomized study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy. J Am Acad Dermatol 1996; 34: 595-600.
12. Gupta AK, Scher RK. Oral antifungal agents for onychomycosis. Lancet 1998; 351: 541-2.
13. Evans EGV, Sigurgeirsson B. for the L.I.ON. study group. Double blind, randomised study comparing continuous terbinafine with intermittent itraconazole in the treatment of toenail onychomycosis. Br Med J 1999; 318: 1031-5.
14. Ryder NS, Favre B. Antifungal activity and mechanism of action of terbinafine. Rev Contemp Pharmacother 1997; 8: 275-87.
15. Hazen K, Fungicidal versus fungistatic activity of terbinafine and itraconazole: an in vitro comparison. J Am Acad Dermatol 1998; 38: S37-S41.
16. Clayton YM. In vitro activity of terbinafine. Clin Exp Dermatol 1989; 14: 101-3.
17. Finlay AY, Lever L, Thomas R, Dykes PJ. Nail matrix kinetics of oral terbinafine in onychomycosis and normal nails. J Dermatol Treat 1990; 1 (Suppl. 2): 51-3.
18. Gupta AK, Sauder DN, Shear NH. Antifungal agents: an overview. Part II. J Am Acad Dermatol 1994; 30: 911-33.
19. Hall M, Monka C, Krupp P. O'Sullivan C. Safety of oral terbinafine. Results of a postmarketing surveillance study in 25, 884 patients. Arch Dermatol 1997; 133: 1213-1219.
20. Suhonen R, Neuvonen PJ. The tolerability profile of terbinafine. Rev Contemp Pharmacother 1997; 8: 373-386.